Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11759
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRowe, Christopher C-
dc.contributor.authorVillemagne, Victor L-
dc.date.accessioned2015-05-16T01:23:11Z-
dc.date.available2015-05-16T01:23:11Z-
dc.date.issued2013-05-01-
dc.identifier.citationThe Medical Clinics of North America; 97(3): 377-98en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/11759en
dc.description.abstractIn vivo imaging of amyloid-β (Aβ) with positron emission tomography has moved from the research arena into clinical practice. Clinicians working with cognitive decline and dementia must become familiar with its benefits and limitations. Amyloid imaging allows earlier diagnosis of Alzheimer disease and better differential diagnosis of dementia and provides prognostic information for mild cognitive impairment. It also has an increasingly important role in therapeutic trial recruitment and for evaluation of anti-Aβ treatments. Longitudinal observations are required to elucidate the role of Aβ deposition in the course of Alzheimer disease and provide information needed to fully use the prognostic power of this investigation.en
dc.language.isoenen
dc.subject.otherAgeden
dc.subject.otherAlzheimer Disease.genetics.pathology.radionuclide imagingen
dc.subject.otherAmyloid beta-Peptides.analysis.geneticsen
dc.subject.otherAniline Compounds.diagnostic useen
dc.subject.otherAsymptomatic Diseasesen
dc.subject.otherBrain.pathology.radionuclide imagingen
dc.subject.otherCarbon Radioisotopes.diagnostic useen
dc.subject.otherChromosome Aberrationsen
dc.subject.otherDNA Mutational Analysisen
dc.subject.otherDiagnosis, Differentialen
dc.subject.otherDisease Progressionen
dc.subject.otherFluorine Radioisotopes.diagnostic useen
dc.subject.otherHeterozygote Detectionen
dc.subject.otherHumansen
dc.subject.otherMild Cognitive Impairment.genetics.pathology.radionuclide imagingen
dc.subject.otherPositron-Emission Tomographyen
dc.subject.otherPrognosisen
dc.subject.otherStatistics as Topicen
dc.subject.otherThiazoles.diagnostic useen
dc.titleAmyloid imaging with PET in early Alzheimer disease diagnosis.en
dc.typeJournal Articleen
dc.identifier.journaltitleThe Medical clinics of North Americaen
dc.identifier.affiliationDepartment of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationUniversity of Melbourne, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.1016/j.mcna.2012.12.017en
dc.description.pages377-98en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/23642577en
dc.type.contentTexten
dc.type.austinJournal Articleen
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

10
checked on Jan 27, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.